Mouse Monoclonal to CD79a HM47 (IgG1)

Background

CD79a (Ig alpha, MB1) forms disulfide-linked heterodimer with CD79b (Ig beta). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

Entrez Gene (human): 19q13.2
Entrez Gene (bovine): 18
Entrez Gene (mouse): 7 5.5 cM

Specificity

The mouse monoclonal antibody HM47 reacts with intracellular domain of CD79a (Ig alpha), a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms.

Regulatory Status

RUO

Immunogen

Synthetic peptide corresponding to C terminal amino acids 208-222 of human CD79a

Species Reactivity: Human Non-Human Primates Porcine Mouse Rat Bovine Guinea pig Canine (Dog) Equine (Horse) Rabbit Chicken Negative Species:

Applications: Flow CytometryApplication note: intracellular staining Immunoprecipitation Western Blotting Immunohistochemistry (paraffin sections) Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References *Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al.: The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J Immunol. 1991 Dec 1;147(11):2474-82. [Abstract] *Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A: CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol. 2007 Aug;128(2):306-13. [Abstract] [Full Text] *Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7. [Abstract] [Full Text] *Fernandez NJ, West KH, Jackson ML, Kidney BA: Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors. Vet Pathol. 2005 Jul;42(4):437-45. [Abstract] [Full Text] *Torlakovic E, Torlakovic G: B-cell markers in lymphocyte predominance Hodgkin disease. Arch Pathol Lab Med. 2002 Jul;126(7):862-3. [Abstract] [Full Text] *Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP: C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology. Int J Clin Exp Pathol. 2008 Jan 1;1(1):65-74. [Abstract] [Full Text] *Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P, Netto G, Garcia JV: Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol. 2004 Dec;78(24):13891-900. [Abstract] [Full Text]